BioCryst Pharmaceuticals (BCRX) Competitors

BioCryst Pharmaceuticals logo
$7.45 -0.16 (-2.10%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$7.55 +0.10 (+1.37%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BCRX vs. PRAX, CYTK, ABVX, ALKS, and RYTM

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? BioCryst Pharmaceuticals's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Abivax (ABVX), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

BioCryst Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M1,014.27-$303.27M-$12.80N/A
BioCryst Pharmaceuticals$874.84M2.19$263.86M-$1.42N/A

Praxis Precision Medicines has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $656.42, suggesting a potential upside of 111.56%. BioCryst Pharmaceuticals has a consensus target price of $20.38, suggesting a potential upside of 173.49%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
3 Strong Buy rating(s)
2.95
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

In the previous week, Praxis Precision Medicines had 27 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 30 mentions for Praxis Precision Medicines and 3 mentions for BioCryst Pharmaceuticals. Praxis Precision Medicines' average media sentiment score of 0.66 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
5 Very Positive mention(s)
7 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -37.40%. Praxis Precision Medicines' return on equity of -29.41% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -29.41% -28.19%
BioCryst Pharmaceuticals -37.40%-92.91%66.56%

Summary

Praxis Precision Medicines beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Cytokinetics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

In the previous week, Cytokinetics had 10 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 13 mentions for Cytokinetics and 3 mentions for BioCryst Pharmaceuticals. Cytokinetics' average media sentiment score of 0.60 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Cytokinetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.38, indicating a potential upside of 173.49%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 100.61%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

BioCryst Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$874.84M2.19$263.86M-$1.42N/A
Cytokinetics$88.04M84.13-$784.96M-$6.04N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a net margin of -37.40% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals-37.40% -92.91% 66.56%
Cytokinetics -686.63%N/A -48.26%

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

BioCryst Pharmaceuticals beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Abivax?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 3 articles in the media. Abivax's average media sentiment score of 1.13 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abivax
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Abivax has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$874.84M2.19$263.86M-$1.42N/A
AbivaxN/AN/A-$380.27M-$6.06N/A

Abivax has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -37.40%. Abivax's return on equity of -91.69% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals-37.40% -92.91% 66.56%
Abivax N/A -91.69%-71.96%

BioCryst Pharmaceuticals presently has a consensus target price of $20.38, suggesting a potential upside of 173.49%. Abivax has a consensus target price of $155.00, suggesting a potential upside of 85.38%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Abivax on 8 of the 15 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Alkermes?

Alkermes (NASDAQ:ALKS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alkermes has a net margin of -0.02% compared to BioCryst Pharmaceuticals' net margin of -37.40%. Alkermes' return on equity of 0.40% beat BioCryst Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes-0.02% 0.40% 0.19%
BioCryst Pharmaceuticals -37.40%-92.91%66.56%

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B5.29$241.66M-$0.02N/A
BioCryst Pharmaceuticals$874.84M2.19$263.86M-$1.42N/A

Alkermes currently has a consensus target price of $55.73, suggesting a potential upside of 19.96%. BioCryst Pharmaceuticals has a consensus target price of $20.38, suggesting a potential upside of 173.49%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56

Alkermes has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

In the previous week, Alkermes had 14 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 17 mentions for Alkermes and 3 mentions for BioCryst Pharmaceuticals. Alkermes' average media sentiment score of 0.85 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Alkermes beats BioCryst Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Rhythm Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for BioCryst Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.76 beat BioCryst Pharmaceuticals' score of 0.56 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioCryst Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rhythm Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals currently has a consensus price target of $20.38, indicating a potential upside of 173.49%. Rhythm Pharmaceuticals has a consensus price target of $142.00, indicating a potential upside of 32.12%. Given BioCryst Pharmaceuticals' higher possible upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77

BioCryst Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$874.84M2.19$263.86M-$1.42N/A
Rhythm Pharmaceuticals$189.76M39.27-$196.54M-$2.90N/A

BioCryst Pharmaceuticals has a net margin of -37.40% compared to Rhythm Pharmaceuticals' net margin of -69.03%. BioCryst Pharmaceuticals' return on equity of -92.91% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals-37.40% -92.91% 66.56%
Rhythm Pharmaceuticals -69.03%-171.16%-43.00%

Summary

BioCryst Pharmaceuticals beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCRX vs. The Competition

MetricBioCryst PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.98B$4.15B$7.84B$12.17B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio-5.2527.6734.7128.60
Price / Sales2.1916.368.635.70
Price / Cash6.2026.3721.9322.50
Price / Book-4.844.074.323.70
Net Income$263.86M-$22.86M$3.52B$392.17M
7 Day Performance-1.06%-6.13%-4.44%-3.21%
1 Month Performance-4.36%-4.90%-3.49%-5.66%
1 Year Performance5.97%-2.99%0.19%-5.97%

BioCryst Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCRX
BioCryst Pharmaceuticals
2.5383 of 5 stars
$7.45
-2.1%
$20.38
+173.5%
+5.2%$1.98B$874.84MN/A435
PRAX
Praxis Precision Medicines
2.8992 of 5 stars
$332.97
+19.9%
$630.42
+89.3%
+66.4%$7.95B$8.55MN/A168
CYTK
Cytokinetics
3.054 of 5 stars
$55.14
+2.7%
$106.67
+93.4%
-20.0%$7.91B$88.04MN/A673
ABVX
Abivax
3.2508 of 5 stars
$87.00
+1.5%
$155.00
+78.2%
-24.3%$7.83BN/AN/A98
ALKS
Alkermes
2.5734 of 5 stars
$46.17
+0.6%
$55.06
+19.3%
+60.0%$7.71B$1.48B1,529.672,050

Related Companies and Tools


This page (NASDAQ:BCRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners